US nutrition and health experts predict that the expansion of GLP-1 medications will make the most significant impact in 2026. A U.S. News & World Report survey of 58 experts indicated that these medications will increasingly be used for managing chronic conditions beyond obesity and type 2 diabetes, including heart health, kidney disease, and addiction treatment. Over half of respondents (52%) pointed to the expanded use of GLP-1s as the key health trend for this year, followed by a greater use of “Food as Medicine” (38%), AI integration with wearable technology (38%), a focus on nutrition for the gut microbiome (33%), and personalized nutrition (12%).
